BioNTech Raises $270M Series A Round To Pursue FIPCO Model
German biotech BioNTech has raised $270m in a Series A round as it seeks to broaden its investor base and finance its ambition to be a global, fully integrated pharmaceutical company (FIPCO). In the past nine years the company has secured $950m – including a $180m seed financing in 2008, various research grants ($50m), and upfront and near-term milestone payments from partners ($450m).
You may also be interested in...
Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.